Home › Brain Tumors › Montana › Great Falls
Brain Tumors clinical trials in Great Falls, MT
3 studies for Brain Tumors are looking for participants at sites in and around Great Falls (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RecruitingPhase 2
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
- Great Falls Clinic, Great Falls
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
RecruitingPhase 3
- Benefis Sletten Cancer Institute, Great Falls
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RecruitingPhase 3
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
About Brain Tumors
A brain tumor is a growth of abnormal cells in the brain tissue. Learn the types of tumors, symptoms, how they are diagnosed and treatment options.
More about Brain Tumors on MedlinePlus
Brain Tumors trials in other cities
- Houston, TX35 studies
- Boston, MA28 studies
- New York City, NY25 studies
- Washington, DC20 studies
- Los Angeles, CA16 studies
- Miami, FL15 studies
- Durham, NC14 studies
- St. Louis, MO12 studies
- Cleveland, OH11 studies
- Seattle, WA11 studies
- Rochester, MN11 studies
- Baltimore, MD11 studies
Other studies in Great Falls
- Prostate Cancer10 studies
- Non-Small Cell Lung Cancer9 studies
- Lung Cancer9 studies
- Acute Myeloid Leukemia6 studies
- Colorectal Cancer5 studies
- Head and Neck Squamous Cell Carcinoma5 studies
- Melanoma5 studies
- Breast Cancer5 studies
- Bladder Cancer5 studies
- Colon Cancer4 studies
- Endometrial Cancer3 studies
- Kidney Cancer (Renal Cell Carcinoma)3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.